PROSPECTIVE SERIAL ANALYSIS OF INTERLEUKIN-2 AND SOLUBLE INTERLEUKIN-2 RECEPTOR IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS

被引:15
作者
FREEDMAN, MS
MUTH, KL
TROTTER, JL
YOSHIZAWA, CN
ANTEL, JP
机构
[1] ABBOTT LABS,DIV DIAGNOST,N CHICAGO,IL 60064
[2] WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110
[3] BERLEX LABS INC,ALAMEDA,CA
关键词
D O I
10.1212/WNL.42.8.1596
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We performed a longitudinal analysis of serum interleukin-2 (IL-2) and soluble IL-2 (sIL-2R) concentrations in 60 patients with relapsing-remitting (R-R) multiple sclerosis (MS) as well as in 33 age- and sex-matched normal controls. Overall, we found that serum IL-2 levels remained low (< 10 U/ml) and did not change appreciably over time; however, marked fluctuations in sIL-2R levels were observed in both the patient and control groups. Using patients as their own controls, we calculated an interrelapse (disease stable) mean sIL-2R concentration as a baseline for comparison with relapse values; sIL-2R levels greater than the 90th percentile of the Student's t distribution of stable values were defined as "peaks." There were a total of 27 sIL-2R peaks, eight (30%) of which correlated with clinical relapses but were potentially predictive of only 18% (8/45) of all the recorded clinical relapses. There was no difference in disease severity (Expanded Disability Status Scale) score between peak-correlated and noncorrelated relapses. Our data suggest that despite reports of elevated levels of IL-2 and sIL-2R in MS, neither may be a useful marker for predicting clinical disease activity in R-R MS.
引用
收藏
页码:1596 / 1601
页数:6
相关论文
共 25 条
  • [1] ADACHI K, 1988, LANCET, V1, P559
  • [2] ADAMS DH, 1989, LANCET, V1, P469
  • [3] SERUM LEVELS OF INTERLEUKIN-2 RECEPTOR AND ACTIVITY OF RHEUMATIC DISEASES CHARACTERIZED BY IMMUNE-SYSTEM ACTIVATION
    CAMPEN, DH
    HORWITZ, DA
    QUISMORIO, FP
    EHRESMANN, GR
    MARTIN, WJ
    [J]. ARTHRITIS AND RHEUMATISM, 1988, 31 (11): : 1358 - 1364
  • [4] SIGNIFICANTLY HIGHER LEVELS OF SOLUBLE INTERLEUKIN-2 IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE-SCLEROSIS COMPARED WITH HEALTHY-SUBJECTS
    CAPRA, R
    MATTIOLI, F
    MARCIANO, N
    VIGNOLO, LA
    BETTINZIOLI, M
    AIRO, P
    CATTANEO, R
    [J]. ARCHIVES OF NEUROLOGY, 1990, 47 (03) : 254 - 254
  • [5] PLASMA INTERLEUKIN-2 RECEPTOR LEVELS IN RENAL-ALLOGRAFT RECIPIENTS
    COLVIN, RB
    FULLER, TC
    MACKEEN, L
    KUNG, PC
    IP, SH
    COSIMI, AB
    [J]. CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1987, 43 (02): : 273 - 276
  • [6] INTERLEUKIN-2 LEVELS IN SERUM AND CEREBROSPINAL-FLUID OF MULTIPLE-SCLEROSIS PATIENTS
    GALLO, P
    PICCINNO, M
    PAGNI, S
    TAVOLATO, B
    [J]. ANNALS OF NEUROLOGY, 1988, 24 (06) : 795 - 797
  • [7] IMMUNE ACTIVATION IN MULTIPLE-SCLEROSIS - STUDY OF IL-2, SIL-2R, AND GAMMA-IFN LEVELS IN SERUM AND CEREBROSPINAL-FLUID
    GALLO, P
    PICCINNO, MG
    PAGNI, S
    ARGENTIERO, V
    GIOMETTO, B
    BOZZA, F
    TAVOLATO, B
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 1989, 92 (01) : 9 - 15
  • [8] A LONGITUDINAL-STUDY ON IL-2, SIL-2R, IL-4 AND IFN-GAMMA IN MULTIPLE-SCLEROSIS CSF AND SERUM
    GALLO, P
    PICCINNO, MG
    TAVOLATO, B
    SIDEN, A
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 1991, 101 (02) : 227 - 232
  • [9] GREENBERG SJ, 1988, NEW ENGL J MED, V319, P1019
  • [10] T-CELL ACTIVATION IN GUILLAIN-BARRE-SYNDROME AND IN MS - ELEVATED SERUM LEVELS OF SOLUBLE IL-2 RECEPTORS
    HARTUNG, HP
    HUGHES, RAC
    TAYLOR, WA
    HEININGER, K
    REINERS, K
    TOYKA, KV
    [J]. NEUROLOGY, 1990, 40 (02) : 215 - 218